Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
- Revenue in NZD (TTM)195.41m
- Net income in NZD15.61m
- Incorporated1997
- Employees110.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttp://www.aftpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ouro Fino Saude Animal Participacoes SA | 284.16m | -10.04m | 299.21m | 1.01k | -- | 1.43 | 285.77 | 1.05 | -0.6271 | -0.6271 | 17.75 | 13.03 | 0.7329 | 1.82 | 4.93 | -- | -2.59 | 5.93 | -3.17 | 7.48 | 46.45 | 49.30 | -3.53 | 7.80 | 2.55 | 59.00 | 0.3749 | 16.83 | -9.40 | 9.87 | -138.25 | -- | -0.2692 | 14.07 |
Qinghai Spring Medicinl Rsrcs Tech CoLTD | 54.42m | -59.82m | 306.24m | 173.00 | -- | 1.10 | -- | 5.63 | -0.4532 | -0.4532 | 0.4123 | 2.11 | 0.1698 | 0.3652 | 5.52 | 1,399,016.00 | -18.54 | -11.25 | -19.08 | -11.55 | 56.22 | 23.44 | -109.22 | -129.81 | 9.93 | -0.8261 | 0.0139 | -- | 33.52 | -8.48 | 6.85 | -- | -20.83 | -- |
Elite Pharmaceuticals Inc | 77.33m | 25.42m | 306.88m | 53.00 | 12.09 | 4.05 | 11.11 | 3.97 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
Jiangsu gdk Biotechnology Co Ltd | 7.51m | -28.97m | 307.49m | 451.00 | -- | 1.01 | -- | 40.96 | -1.04 | -1.04 | 0.2686 | 10.95 | 0.0193 | 0.4185 | 0.1529 | 74,034.57 | -7.45 | 3.30 | -8.73 | 4.84 | 51.14 | 75.56 | -385.83 | 12.58 | 3.20 | -- | 0.048 | 32.60 | -57.74 | -- | -270.88 | -- | 54.07 | -- |
AFT Pharmaceuticals Ltd | 195.41m | 15.61m | 309.36m | 110.00 | 19.82 | 3.52 | 17.56 | 1.58 | 0.1489 | 0.1489 | 1.86 | 0.8372 | 1.25 | 2.34 | 4.30 | 1,776,464.00 | 9.96 | 11.44 | 13.72 | 16.49 | 45.17 | 45.65 | 7.99 | 9.50 | 1.23 | 6.69 | 0.2683 | 4.43 | 24.75 | 18.08 | 46.51 | -- | 22.42 | -- |
Zota Health Care Ltd | 35.32m | -2.81m | 313.73m | 338.00 | -- | 17.36 | 279.10 | 8.88 | -5.59 | -5.59 | 70.40 | 34.81 | 0.9341 | 2.02 | 6.55 | -- | -7.42 | -1.38 | -10.54 | -1.85 | 46.43 | 36.48 | -7.95 | -1.33 | 0.7851 | -2.62 | 0.5143 | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
Inhibrx Biosciences Inc | 2.91m | -443.14m | 317.95m | 166.00 | -- | 57.20 | -- | 109.12 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Holder | Shares | % Held |
---|---|---|
Accident Compensation Corp.as of 15 May 2024 | 6.34m | 6.05% |
Guardians of New Zealand Superannuationas of 30 Apr 2023 | 1.69m | 1.62% |
FCA Corp.as of 30 Apr 2024 | 46.00k | 0.04% |
Dimensional Fund Advisors LPas of 06 Jun 2024 | 39.19k | 0.04% |